In classical Hodgkin’s lymphoma (cHL) the existing prognostic
scoring systems do not include markers that adequately reflect the
interaction of malignant Hodgkin and Reed-Sternberg (HRS) cells
and tumor environment. The research objective is to determine the
relationship between serum Galectin-1 (Gal-1) and soluble CD163
(sCD163) and the clinical status of patients with cHL, with special
emphasis on the presence of relapse, progression, or resistance to the
therapy applied. The research included 79 patients. Of this number,
63 were patients with cHL, and the control group consisted of 16
healthy volunteers. The study group of 63 patients with cHL included
a subgroup of newly diagnosed patients without therapy, newly
diagnosed patients with therapy, patients with relapse and progression
of the disease, and primary refractory patients during 2014 and 2015.
Analysis of the levels of sCD163 and sGal-1 within a group of
patients suffering from cHL has shown that the values of both
molecules were higher in relapsed patients and the subgroup with
progressive disease comparing the subgroup of newly diagnosed
patients without therapy or patients with therapy onset. Determination
of Gal-1 and sCD163 levels is simple and reliable analysis that can
contribute to the identification of high-risk patients with cHL, and
deserves inclusion in current prognostic scoring systems
